Anti-idiotypic Patents (Class 530/387.2)
-
Publication number: 20110250204Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: October 8, 2010Publication date: October 13, 2011Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Paul A. MOORE, Tao HE, Candy N. LEE, Karen VAN ORDEN, Charles E. Birse, Mehdi Mesri, Elizabeth G. Joseloff
-
Patent number: 8034338Abstract: The invention refers to an immunogenic recombinant antibody designed for immunization of primates comprising at least a part of a murine IgG2a subtype amino acid sequence and a mammalian glycosylation.Type: GrantFiled: April 16, 2004Date of Patent: October 11, 2011Assignee: Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-AGInventors: Hans Loibner, Gottfried Himmler, Günter Waxenecker, Manfred Schuster, Thomas Putz
-
Publication number: 20110245468Abstract: B7-HS costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.Type: ApplicationFiled: February 28, 2011Publication date: October 6, 2011Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventor: Lieping Chen
-
Publication number: 20110236373Abstract: The present invention relates, in general, to HIV and, in particular to a method of detecting anti-HIV antibodies and antibody-HIV virion complexes.Type: ApplicationFiled: September 24, 2009Publication date: September 29, 2011Inventors: Georgia Tomaras, Barton F. Haynes, Liu Pinghuang, Nicole Yates, Kwan-Ki Hwang
-
Publication number: 20110229489Abstract: The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the KD or koff ratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent KDs at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound.Type: ApplicationFiled: March 10, 2011Publication date: September 22, 2011Inventors: Jaume Pons, Jeffrey Raymond Chabot, Javier Fernando Chaparro Riggers, Bruce Charles Gomes, Hong Liang, Kapil Mayawala, Jerome Thomas Mettetal, II, Arvind Rajpal, David Louis Shelton
-
Publication number: 20110219464Abstract: The present invention provides a method for diagnosing and detecting diseases associated with lung. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in lung cancer (LCAT) and antibodies binds to LCATs. The present invention provides that LCATs are used as targets for screening agents that modulates the LCAT activities. Further the present invention provides methods for treating diseases associated with lung.Type: ApplicationFiled: August 25, 2010Publication date: September 8, 2011Applicant: CELERA CORPORATIONInventors: Bruno DOMON, Elizabeth JOSELOFF, Aiqun LI, Tao HE
-
Publication number: 20110217291Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.Type: ApplicationFiled: June 29, 2009Publication date: September 8, 2011Inventors: Carl W. Birks, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
-
Publication number: 20110212084Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.Type: ApplicationFiled: February 15, 2008Publication date: September 1, 2011Applicants: ASTRAZENECA AB, MEDIMMUNE LIMITEDInventors: Duncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
-
Publication number: 20110212087Abstract: Antibody and other Fc-containing molecules with variations in the Fc region reduce binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.Type: ApplicationFiled: November 29, 2010Publication date: September 1, 2011Inventors: William Strohl, Omid Vafa
-
Publication number: 20110212085Abstract: The present invention provides a method for diagnosing and detecting diseases associated with lung. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in lung diseases (LCAT) and antibodies binds to LCATs. The present invention provides that LCATs are used as targets for screening agents that modulates the LCAT activities. Further the present invention provides methods for treating diseases associated with lung.Type: ApplicationFiled: August 19, 2010Publication date: September 1, 2011Applicant: CELERA CORPORATIONInventors: Elizabeth JOSELOFF, Aiqun LI, Tao HE, Steve RUBEN
-
Publication number: 20110208673Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.Type: ApplicationFiled: February 11, 2011Publication date: August 25, 2011Applicant: Genentech, Inc.Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
-
Publication number: 20110200627Abstract: The present invention provides antibodies immunospecific for human CD 147 capable of blocking bioactivity of CD 147 associated with malignant disease such as the stimulation of MMPs from fibroblast cells by tumor cells, the release of VEGF, and the promotion of angiogenesis. The antibodies of the present invention of are useful in treating malignant disease and those diseases in which CD 147 activity is plays a pathogenic role, such as diseases of the eye, lung, and cardiovascular system.Type: ApplicationFiled: August 19, 2009Publication date: August 18, 2011Inventors: Mark Cunningham, Bethany Swencki-Underwood, Yi Tang, Li Yan
-
Publication number: 20110195438Abstract: The present invention provides an insulin-specific assay and an assay reagent capable of sensitively and specifically assaying insulin using an antibody having a property of reacting with insulin bound to an anti-insulin antibody while not reacting with insulin not bound to an anti-insulin antibody, without being affected by proinsulin and insulin analogs.Type: ApplicationFiled: July 21, 2010Publication date: August 11, 2011Inventors: Junichi Kondou, Tomo Shimizu, Mitsuaki Yamamoto, Yasushi Nakamura
-
Publication number: 20110195062Abstract: Nucleic acids encoding mammalian, e.g., primate, IL-?, purified IL-1? polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.Type: ApplicationFiled: April 18, 2011Publication date: August 11, 2011Applicant: Schering CorporationInventor: Jacqueline C. Timans
-
Patent number: 7994291Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.Type: GrantFiled: May 25, 2010Date of Patent: August 9, 2011Assignee: Amgen Inc.Inventors: Hui-Quan Han, Keith Kwak
-
Publication number: 20110183363Abstract: The invention provides methods and reagents useful for detecting anti-drug antibodies of IgE isotype to therapeutic anti-IgE antibodies, and methods for assessing risk of anaphylaxis to administration of a therapeutic anti-IgE antibody.Type: ApplicationFiled: October 26, 2010Publication date: July 28, 2011Inventors: Saloumeh Fischer, Dana L. Baker, Henry B. Lowman, Gerald R. Nakamura
-
Publication number: 20110184150Abstract: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.Type: ApplicationFiled: April 1, 2011Publication date: July 28, 2011Applicant: Ablynx N.V.Inventors: Karen Silence, Marc Lauwereys, Hans De Haard
-
Publication number: 20110178277Abstract: The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.Type: ApplicationFiled: April 1, 2011Publication date: July 21, 2011Applicant: Ablynx N.V.Inventors: Karen Silence, Marc Jozef Lauwereys, Torsten Dreier
-
Publication number: 20110177977Abstract: The present invention is directed to antibodies having specificity for a heavy chain class at the same time as having specificity for a first light chain. Such antibodies can be used in a method of detecting or monitoring a malignant plasma cell disease comprising determining in a sample the ratio between the relative amounts of immunoglobulins having: (i) a heavy chain class bound to ? light chains; and (ii) immunoglobulins having the same heavy chain class but bound to ? light chains.Type: ApplicationFiled: January 21, 2011Publication date: July 21, 2011Applicant: THE BINDING SITE GROUP LIMITEDInventor: Arthur R. BRADWELL
-
Publication number: 20110165701Abstract: An objective of the present invention is to provide an anti-human IgM monoclonal antibody that is capable of reacting specifically with human IgM and inducing immunoagglutination based on an antigen-antibody reaction with human IgM in solution, and an immunoassay using the said monoclonal antibody. Another objective of the present invention is to provide an agent for suppressing non-specific reactions caused by human IgM that could not be prevented by conventional methods, and an immunoassay in which non-specific reactions caused by human IgM are suppressed. By selecting a monoclonal antibody that reacts with human IgM on the basis of evaluation of reactivity with human IgM in solution, a novel monoclonal antibody capable of agglutinating human IgM by itself and performing a practical immunoagglutination assay has been obtained, and the objectives above have been thus achieved.Type: ApplicationFiled: September 3, 2009Publication date: July 7, 2011Inventors: Yuki Takahashi, Tomo Shimizu, Hiroshi Takahashi, Yasushi Nakamura
-
Publication number: 20110158981Abstract: The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals.Type: ApplicationFiled: March 7, 2011Publication date: June 30, 2011Inventors: Eugene Regis Krah, III, Robert Lawton
-
Publication number: 20110158902Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.Type: ApplicationFiled: January 24, 2011Publication date: June 30, 2011Applicant: NEOGENIX ONCOLOGY, INC.Inventors: Myron ARLEN, J. Andrew Bristol, Ariel C. Hollinshead, Kwong Y. Tsang
-
Publication number: 20110129457Abstract: The present invention is directed to derivatives of Hhip1 and methods of using the same for treatment and diagnosis of cancer in mammals.Type: ApplicationFiled: June 1, 2009Publication date: June 2, 2011Inventors: Ivan Bosanac, Sarah G. Hymowitz, Robert A. Lazarus, Henry R. Maun, Suzanna J. Scales, Xiaohui Wen
-
Publication number: 20110129416Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.Type: ApplicationFiled: January 24, 2011Publication date: June 2, 2011Applicant: NEOGENIX ONCOLOGY, INC.Inventors: J. Andrew BRISTOL, Judith A. Kantor
-
Publication number: 20110104818Abstract: Methods for characterizing a test subject's, particularly a human test subject's, risk of having cardiovascular disease or developing cardiovascular disease are provided. Also provided are methods for characterizing a test subject's risk of experiencing a complication of cardiovascular disease near term. The methods comprise determining levels of one or more carbamylated biomarkers in a bodily fluid of the test subject and/or comparing these levels with a reference value. In certain embodiments, the carbamylated biomarkers are carbamylated albumin, carbamylated fibrinogen, carbamylated immunoglobulin and carbamylated apolipoprotein A. In other embodiments, particularly where the test subject does not have clinical evidence of renal disease, the carbamylated biomarker is free and/or total peptide-bound homocitrulline.Type: ApplicationFiled: August 28, 2008Publication date: May 5, 2011Applicant: The Cleveland Clinic FoundationInventors: Stanley L. Hazen, Zeneng Wang, Stephen James Nicholls, Joe Didonato
-
Publication number: 20110104059Abstract: To gain a better understanding of tumor angiogenesis endothelial cells (ECs) were isolated and gene expression patterns were evaluated. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed differentially expressed genes, including many that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level.Type: ApplicationFiled: May 6, 2009Publication date: May 5, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Brad ST. CROIX, Kenneth W. KINZLER, Bert VOGELSTEIN
-
Publication number: 20110104152Abstract: The present invention is directed to novel chimeric fibroblast growth factor (FGF) polypeptides, novel DNA encoding chimeric FGF polypeptides, and to the recombinant production of chimeric FGF polypeptides, and to methods, compositions and assays utilizing chimeric FGF polypeptides for the therapeutic treatment of metabolic-related disorders and other conditions, and for producing pharmaceutically active compositions including chimeric FGF polypeptides, the compositions having therapeutic and pharmacologic properties including those associated with the treatment of metabolic-related disorders and other conditions.Type: ApplicationFiled: October 15, 2010Publication date: May 5, 2011Inventor: Junichiro SONODA
-
Patent number: 7935796Abstract: Monoclonal antibodies that specifically bind to ANGPTL3 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL3 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.Type: GrantFiled: December 6, 2007Date of Patent: May 3, 2011Assignee: Lexicon Pharmaceuticals, Inc.Inventors: E-Chiang Lee, Gregory Landes, Seokjoo Hong, Urvi Desai, David Powell, Xiao Feng
-
Publication number: 20110098448Abstract: The invention relates to an antibody, antibody fragment or derivative thereof which specifically recognizes a prion protein and which comprises a complementarity determining region (CDR), a retro-inverso D-peptide of said CDR and/or an anti-idiotypic antibody, antibody fragment or derivative thereof which recognizes said CDR. The invention further concerns a nucleic acid molecule encoding said antibody, antibody fragment or derivative thereof as well as a method for generating an antibody, antibody fragment or derivative thereof that specifically recognizes a prion protein, wherein an antibody that recognizes a specific domain of the prion protein is generated, an antigen-specific amino acid sequence is isolated from said antibody, and an anti-idiotypic antibody, antibody fragment or derivative thereof, which recognizes said antigen-specific amino acid sequence, is generated.Type: ApplicationFiled: June 16, 2009Publication date: April 28, 2011Inventors: Carsten Korth, Lothar Stitz, Benjamin Petsch, Andreas Muller-Schiffmann, Sirik Rutger Leliveld
-
Publication number: 20110099647Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: September 21, 2010Publication date: April 28, 2011Applicant: GENMAB A/SInventors: Michel DE WEERS, Yvo GRAUS, Judith OPRINS, Paul PARREN, Jan VAN DE WINKEL, Martine VAN VUGT
-
Publication number: 20110091449Abstract: This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.Type: ApplicationFiled: May 9, 2008Publication date: April 21, 2011Inventors: Aimee S. Payne, John R. Stanley, Donald L. Siegel, Ken Ishii
-
Publication number: 20110093962Abstract: The present invention provides a method for diagnosing and detecting diseases associated with breast. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in breast diseases (BCAT) and antibodies binds to BCAT. The present invention provides that BCAT is used as targets for screening agents that modulates the BCAT activities. Further the present invention provides methods for treating diseases associated with breast.Type: ApplicationFiled: October 22, 2010Publication date: April 21, 2011Applicant: CELERA CORPORATIONInventors: Jenny HEIDBRINK, Steve RUBEN, Charles E. BIRSE, Tao HE
-
Publication number: 20110082094Abstract: A mammalian cytokine-like polypeptide, called Zcyto10, polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.Type: ApplicationFiled: September 27, 2010Publication date: April 7, 2011Inventors: Darrell C. Conklin, Betty A. Haldeman, Angelika Grossmann
-
Publication number: 20110076265Abstract: A monoclonal antibody directed against the influenza A virus is described, which is capable of binding human and animal isolates of influenza A viruses expressing the H1-subtype hemagglutinin. A preferred embodiment is the antibody designated as Fab49, which shows a neutralizing activity against a plurality of influenza A virus isolates expressing the H1-subtype hemagglutinin, including animal-derived isolates. Anti-idiotype antibodies directed against the monoclonal antibody of the invention, immunogenic or vaccine compositions comprising the monoclonal antibody of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibody of the invention. The monoclonal antibody of the invention can also be employed for testing antibody preparations to be used as vaccines.Type: ApplicationFiled: May 27, 2009Publication date: March 31, 2011Inventors: Roberto Burioni, Massimo Clementi
-
Publication number: 20110076264Abstract: The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG protease cleavage products to restore effector function to antibody compositions that are subject to protease cleavage.Type: ApplicationFiled: November 19, 2010Publication date: March 31, 2011Inventors: Robert Jordan, David Knight, Randall Brezski
-
Publication number: 20110064725Abstract: The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: ApplicationFiled: March 27, 2009Publication date: March 17, 2011Inventors: Sanjaya Singh, Herren Wu, Catherine Foster
-
Publication number: 20110064726Abstract: The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies.Type: ApplicationFiled: November 24, 2010Publication date: March 17, 2011Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Wai Liu, Mike Yeadon, Isabelle de Mendez, Alison Logan, Gerald F. Casperson, Arvind Rajpal, Mark A. Moffat, Wei Liao, Caroline Brown, Nurten Beyaz-Kavuncu, Judith Diaz-Collier, Sirid-Aimee Kellermann
-
Publication number: 20110044974Abstract: The object of the present invention is analogues of peptides or parent proteins, these peptide analogues, comprising at least one aza-?3 aminoacyl residue, and also their uses in pharmaceutical compositions or for the diagnosis of pathologies wherein the aforesaid peptides or parent proteins are involved.Type: ApplicationFiled: June 11, 2004Publication date: February 24, 2011Inventors: Michele Baudy Floc'h, Olivier Busnel, Sylviane Muller
-
Patent number: 7892542Abstract: This invention relates to human anti-idiotypic antibody fragments, especially scFv, characterized by the ability to mimic Her-2/neu tumor associated antigen. These antibody fragments are promising candidates for active immunotherapy for cancer patients positive for Her-2/neu.Type: GrantFiled: December 14, 2004Date of Patent: February 22, 2011Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre Regional de Lutte Contre le Cancer “Val d'Aurelle-Paul Lamarque”, Universite Montpellier IInventors: Philippe Gauthier, André Pelegrin, Mickaël Coelho, Isabelle Teulon
-
Publication number: 20110038869Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: December 19, 2008Publication date: February 17, 2011Applicant: GENMAB A/SInventors: Edward Norbert Van Den Brink, Paul Parren, Jan Van De Winkel, Aran Frank Labrijn, Frank Everhardus Martinus Rebers, Esther Cornelia Wilhelmina Breij
-
Publication number: 20110033838Abstract: The disclosure relates, in some embodiments, to sequences of a novel mutant or variant of the hepatitis B surface antigen (HBsAg) and methods for detecting this genome and protein variant, and antibodies directed against it, from patients' samples.Type: ApplicationFiled: December 16, 2008Publication date: February 10, 2011Inventors: Delia Bussfeld, Anne-Sophie Endres, Helga Meisel, Michael Weik
-
Publication number: 20110033465Abstract: The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9.Type: ApplicationFiled: October 27, 2008Publication date: February 10, 2011Applicant: SCHERING CORPORATIONInventors: Joseph A. Hedrick, Frederick James Monsma, JR., Tatyana Churakova, Diane Hollenbaugh
-
Publication number: 20110033479Abstract: The present invention relates to autoantigens selected from Ezrin, Serpin B5, Peroxiredoxin-2, heat shock protein ?1, and/or peptides comprising at least 5 consecutive amino acid residues of one of these autoantigenic proteins having immunological activity, or fragments, variants, or epitopes thereof and/or mixtures of at least two of the proteins and/or peptides as diagnostic tool for the detection of streptococcal driven conditions or as therapeutical agent for the treatment of streptococcal driven conditions.Type: ApplicationFiled: September 29, 2008Publication date: February 10, 2011Applicant: LUDWIG-MAXIMILIANS-UNIVERSITATInventors: Jörg C. Prinz, Petra Besgen, Paul Trommler
-
Publication number: 20110014117Abstract: The present invention relates in part to anti-IGF1R antibodies and antigen-binding compositions thereof along with methods of use thereof. For example, methods of treating medical disorders such as cancer are covered.Type: ApplicationFiled: June 25, 2008Publication date: January 20, 2011Inventors: Yan Wang, Jonathan A. Pachter, Judith Anne Hailey, Peter Brams, Denise Williams, Mohan Srinivasan, Mary Diane Feingersh
-
Publication number: 20110014187Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.Type: ApplicationFiled: March 16, 2009Publication date: January 20, 2011Inventors: Roberto Burioni, Massimo Clementi
-
Publication number: 20110008326Abstract: The present invention relates to the use of an antigen-binding agent directed against human interleukin-4 receptor for the prevention and/or treatment of tumors, inflammatory and immunological disorders. Further the invention relates to methods of inhibiting the bioactivity of IL-4 without inhibiting binding of IL-4 to IL-4R and particularly to methods for treatment and/or prevention of tumors, inflammatory and immunological disorders, the methods comprising administering to an individual in need thereof an antigen-binding agent with binding affinity for IL-4R.Type: ApplicationFiled: March 30, 2009Publication date: January 13, 2011Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann, Christian Merz
-
Publication number: 20100330076Abstract: Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fe domain that selectively binds Fc?RI at a level within 2-fold of a glycosylated Fc domain, but that is significantly reduced for binding to other Fc receptors. Furthermore, methods and compositions are provided for promoting antibody-dependent cell-mediated toxicity (ADCC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or different non-Fc binding domain.Type: ApplicationFiled: June 30, 2010Publication date: December 30, 2010Inventors: George Georgiou, Sang Taek Jung, Sai Reddy
-
Publication number: 20100325744Abstract: The present invention provides non-glycosylated monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.Type: ApplicationFiled: May 30, 2008Publication date: December 23, 2010Applicant: GENMAB A/SInventors: Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Paul Parren, Willem Karel Bleeker, Patrick Van Berkel, Frank Beurskens
-
Patent number: 7850962Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: April 20, 2005Date of Patent: December 14, 2010Assignee: Genmab A/SInventors: Jessica Teeling, Martin Glennie, Paul Parren, Arnout F. Gerritsen, Sigrid Ruuls, Yvo Graus, Jan van de Winkel
-
Publication number: 20100310551Abstract: The invention relates to an immunogenic antibody which comprises at least two different epitopes of a tumor-associated antigen.Type: ApplicationFiled: March 29, 2010Publication date: December 9, 2010Applicants: MERIDIAN BIOPHARMACEUTICALS GmbH, GREENOVATION BIOTECH GmbHInventors: Hans LOIBNER, Günter WAXENECKER, Gottfried HIMMLER, Helmut ECKERT, Manfred SCHUSTER, Ralf KIRCHEIS